La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Earth Science Tech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Earth Science Tech..

Earth Science Tech (OTC:ETST) Azioni, Catena delle Opzioni

Earth Science Tech Inc is a diversified holding company. The company is set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly-owned subsidiaries.

EARTH SCIENCE TECH INC by Earth Science Tech, Inc.

Earth Science Tech Inc

Mizuho analyst Ann Hynes maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a Neutral and lowers the price target from $12 to $10.

News

Price Target

Analyst Ratings

FTRE

Mizuho Maintains Neutral on Fortrea Holdings, Lowers Price Target to $10

OSRH

Darnatein, A Wholly-owned Subsidiary Of OSR Holdings Announced That It Has Successfully Secured An Additional International Patent For Its Protein-based Osteoarthritis Treatment Technology

Mizuho analyst Ann Hynes maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Outperform and raises the price target from $455 to $505.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Mizuho Maintains Outperform on Elevance Health, Raises Price Target to $505

Benchmark analyst Cody Acree reiterates Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and maintains $8 price target.

Reiteration

INDI

Benchmark Reiterates Buy on Indie Semiconductor, Maintains $8 Price Target

Quest Diagnostics Announced The Launch Of A New Laboratory Blood Test Designed To Help Physicians Confirm Amyloid Brain Pathology Due To Alzheimer's Disease In Patients With Mild Cognitive Impairment Or Dementia

Mizuho maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and raises the price target from $360 to $384.

Mizuho Maintains Outperform on Cigna Group, Raises Price Target to $384

Mizuho analyst Ann Hynes maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $175 to $155.

Mizuho Maintains Neutral on Charles River, Lowers Price Target to $155

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy and maintains $22 price target.

EOLS

Needham Reiterates Buy on Evolus, Maintains $22 Price Target

Mizuho analyst Ann Hynes maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and raises the price target from $70 to $76.

Mizuho Maintains Outperform on CVS Health, Raises Price Target to $76

Needham analyst Gil Blum reiterates Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy and maintains $9 price target.

ABSI

Needham Reiterates Buy on Absci, Maintains $9 Price Target

Xi Jinping&#8216;s China has unveiled a significant hike in retaliatory tariffs on U.S. products, intensifying the ongoing trade war between the world&#8217;s two biggest economies.
What Happened: On Wednesday, China declared that it will raise its reciprocal tariffs on U.S. goods to 84% from the previous 34% from April 10, <a href="https://www.scmp.com/economy/china-economy/article/3305873/china-fires-back-stern-rebuke-trumps-tariff-escalation?module=top_story&amp;pgtype=homepage">reported</a> the South China Morning Post. 
This move comes in the wake of an intensifying trade conflict between the U.S. and China. This comes after the latest U.S. tariff hike — which brings levies on Chinese goods to more than 100% — took effect at the start of April 9.
In response to the new U.S. tariffs, the Ministry of Commerce not only filed a complaint with the World Trade Organization but also added six American companies to its unreliable-entity list. Additionally, it imposed export controls on 12 U.S. firms, prohibiting Chinese companies from supplying them with dual-use items—products that can serve both civilian and military purposes.
"China will firmly defend its interests, multilateral trade system and international economic order," stated the Chinese finance ministry online.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: This announcement comes on the heels of President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/equities/25/04/44704005/trumps-104-tariff-on-chinese-imports-sends-stock-futures-plunging-dow-falls-over-500-points">104% tariff on Chinese imports</a>, which sent stock futures plunging and major indexes to significant lows. 
Despite the escalating trade war, many U.S. companies <a href="https://www.benzinga.com/news/global/25/04/44700937/us-companies-stick-with-china-as-trump-tariffs-take-effect-report">have chosen to stick </a>with their operations in China, viewing it as a strategic value. A report commissioned by the U.S. Chamber of Commerce Foundation revealed that a majority of surveyed firms still see value in maintaining or expanding their presence in China, even as they increasingly view it as their biggest geopolitical risk.
This escalating trade conflict is likely to have far-reaching implications on the global economy, and all eyes are on how this situation will unfold in the coming days.
During the U.S. premarket session, U.S.-listed Chinese stocks traded mixed. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) were in the red, while Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) saw modest gains.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44699720/bitcoin-ethereum-xrp-dogecoin-extend-losses-as-white-house-hammers-chinese-goods-with-104-tariff" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Extend Losses As White House Hammers Chinese Goods With 104% Tariff &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BIDU

XPEV

Xi Jinping Hits Back: China Raises Tariffs On US Goods To 84%, Doubling Down On Trade War

Mizuho analyst Ann Hynes maintains Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) with a Outperform and lowers the price target from $19 to $18.

ARDT

Mizuho Maintains Outperform on Ardent Health Partners, Lowers Price Target to $18

WIIM

PHIO

Phio Pharmaceuticals shares are trading higher after the company announced its Safety Monitoring Committee recommended dose escalation in the Phase 1b trial of PH-762.

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $12 price target.

CRMD

Needham Reiterates Buy on Cormedix, Maintains $12 Price Target

Mizuho analyst James Lee maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and lowers the price target from $285 to $255.

AMZN

Mizuho Maintains Outperform on Amazon.com, Lowers Price Target to $255

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

Biotech

Health Care

General

The Safety Monitoring Committee Recommended Dose Escalation In Phio Pharmaceuticals' Phase 1b Trial For The Company's Lead Product Candidate, PH-762

BTDR

Bitdeer Technologies Reported Self-mined Bitcoin Of 114 (Vs. 294 A Year Ago), Total Hash Rate Under Management (EH/S) Of 24.2 In March 2025 Vs. 22.5 In March 2024

Mizuho analyst James Lee maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Outperform and lowers the price target from $230 to $205.

GOOGL

Mizuho Maintains Outperform on Alphabet, Lowers Price Target to $205

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png" alt="" class="wp-image-10060" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09064759/SDEW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
As smart driving features trickle down to budget cars, the balance of power is shifting to automakers and away from their technology suppliers
China's autonomous driving industry is undergoing a major power shift. As "smart driving equality" emerges as the dominant narrative, a quiet revolution is underway — transitioning the industry from one limited to luxury cars to one with mainstream capabilities across the entire automotive sector.
Major Chinese automakers like&nbsp;BYD&nbsp;(1211.HK; 002594.SZ),&nbsp;NIO&nbsp;(NIO.US; 9866.HK),&nbsp;XPeng&nbsp;(XPEV.US; 9868.HK) and AITO are no longer confining their advanced autonomous driving functions to flagship models. To the contrary, features like navigation on autopilot (NOA), automated parking and city pilot are being rapidly rolled out across mid- and lower-end models priced below 200,000 yuan ($27,400).
While not the first to do so, BYD's launch of its high-level DiPilot system on models costing below 100,000 yuan at the beginning of this year marked a turning point—confirming that the era of smart driving equality had truly arrived.
"In the automotive sector, we believe that full-scale intelligentization will strengthen the global leadership of Chinese brands," said BYD founder Wang Chuanfu. "This is a show of confidence from China's auto industry, and reflects the confidence of Chinese technology."
Historically, high-level autonomous driving was a high-margin business, relying on premium hardware like LiDAR, HD cameras, domain controllers, and powerful chips — typically reserved for luxury models. But as smart driving becomes more accessible, automakers are increasingly taking control of core technologies to protect their profit margins.
BYD's DiPilot, XPeng's XNGP,&nbsp;Li Auto's (LI.US; 2015.HK) AD Max, and Huawei's ADS 2.0 illustrate this shift. Automakers are building their own algorithm teams, mapping systems, and even managing data annotation and simulation training in-house. As a result, upstream suppliers are being pushed to the sidelines, downgraded from solution providers to low-margin parts vendors.
Suppliers like&nbsp;RoboSense&nbsp;(2498.HK) are now offering low-cost solid-state LiDAR and modular solutions.&nbsp;Hesai&nbsp;(HSAI.US) is co-developing customized sensors with automakers.
For suppliers, this is a fight for survival. Without core technologies or the ability to scale, many small and mid-sized vendors face an uphill battle, and are surviving only with razor-thin margins. Only those with system integration, algorithm coordination, and global delivery capabilities are likely to endure.
Behind the push to make advanced autonomous driving available to all lies a quiet industry reshuffling and a redistribution of power. The real winners will be those companies that can not only manufacture vehicles but also master the soul of intelligent driving.

Equities

Travel

Opinion

Tech

Smart Driving Equality: A Battle For Control Of An Emerging Industry

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Buy and lowers the price target from $50 to $37.

Comments

Earth Science Tech

Earth Science Tech (ETST) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO